Keywords
Last Name
Institution

Stephen Silberstein

TitleProfessor
InstitutionThomas Jefferson University
DepartmentNeurology
Address111 S. 11th Street
Philadelphia PA 19107
Phone215-955-2243

 Overview 
 overview
Headache guidelines


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Chua AL, Silberstein S. Inhaled drug therapy development for the treatment of migraine. Expert Opin Pharmacother. 2016 Sep; 17(13):1733-43.
    View in: PubMed
  2. Silberstein SD. The American Headache Society Cluster Guidelines. Headache. 2016 Jul; 56(7):1091-2.
    View in: PubMed
  3. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome: An electronic diary study. Neurology. 2016 Jul 19; 87(3):309-13.
    View in: PubMed
  4. Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache. 2016 Jul; 56(7):1194-200.
    View in: PubMed
  5. Silberstein S. The Management of Adults With Acute Migraine in the Emergency Department. Headache. 2016 Jun; 56(6):907-8.
    View in: PubMed
  6. Piovesan EJ, Oshinsky M, Silberstein S, Kowacs PA, Novak EM, Werneck LC. Botulinum neurotoxin type-A when utilized in animals with trigeminal sensitization induced a antinociceptive effect. Arq Neuropsiquiatr. 2016 Jun; 74(6):462-9.
    View in: PubMed
  7. Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016 Jun; 128(5):523-37.
    View in: PubMed
  8. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr; 15(4):382-90.
    View in: PubMed
  9. Silberstein SD. The Use of Botulinum Toxin in the Management of Headache Disorders. Semin Neurol. 2016 Feb; 36(1):92-8.
    View in: PubMed
  10. Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, Young WB, Silberstein SD, Sharan AD. Long-Term Pain Reduction Does Not Imply Improved Functional Outcome in Patients Treated With Combined Supraorbital and Occipital Nerve Stimulation for Chronic Migraine. Neuromodulation. 2016 Jul; 19(5):507-14.
    View in: PubMed
  11. Berk T, Silberstein S. Case Report: Secondary SUNCT After Radiation Therapy-A Novel Presentation. Headache. 2016 Feb; 56(2):397-401.
    View in: PubMed
  12. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov; 14(11):1081-90.
    View in: PubMed
  13. Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov; 14(11):1091-100.
    View in: PubMed
  14. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part II. Headache. 2016 Feb; 56(2):259-66.
    View in: PubMed
  15. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part III. Headache. 2016 Mar; 56(3):479-90.
    View in: PubMed
  16. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part I. Headache. 2016 Jan; 56(1):71-8.
    View in: PubMed
  17. Silberstein S, Lenz R, Xu C. Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. Headache. 2015 Sep; 55(8):1171-82.
    View in: PubMed
  18. Silberstein SD. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015 Aug; 21(4 Headache):973-89.
    View in: PubMed
  19. Bigal ME, Lipton RB, Newman LC, Pierce MW, Silberstein SD. Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. Headache. 2015 Sep; 55(8):1124-32.
    View in: PubMed
  20. Wrobel Goldberg S, Silberstein SD. Targeting CGRP: A New Era for Migraine Treatment. CNS Drugs. 2015 Jun; 29(6):443-52.
    View in: PubMed
  21. Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J. AVP-825 Breath-Powered Intranasal Delivery System Containing 22?mg Sumatriptan Powder vs 100?mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. Headache. 2015 May; 55(5):621-35.
    View in: PubMed
  22. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015 Mar; 55 Suppl 2:103-22.
    View in: PubMed
  23. St Cyr A, Chen A, Bradley KC, Yuan H, Silberstein SD, Young WB. Efficacy and Tolerability of STOPAIN for a Migraine Attack. Front Neurol. 2015; 6:11.
    View in: PubMed
  24. Silberstein SD, Marmura MJ. Acute migraine treatment. Headache. 2015 Jan; 55(1):1-2.
    View in: PubMed
  25. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan; 55(1):3-20.
    View in: PubMed
  26. Silberstein SD, Silvestrini M. Does migraine produce facial palsy? For whom the Bell tolls. Neurology. 2015 Jan 13; 84(2):108-9.
    View in: PubMed
  27. Vongvaivanich K, Lertakyamanee P, Silberstein SD, Dodick DW. Late-life migraine accompaniments: A narrative review. Cephalalgia. 2015 Sep; 35(10):894-911.
    View in: PubMed
  28. Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015 Sep; 86(9):996-1001.
    View in: PubMed
  29. Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain. 2015 Feb; 16(2):164-75.
    View in: PubMed
  30. Wrobel Goldberg S, Silberstein S, Grosberg BM. Considerations in the treatment of tension-type headache in the elderly. Drugs Aging. 2014 Nov; 31(11):797-804.
    View in: PubMed
  31. Silberstein SD. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp. J Neurol Neurosurg Psychiatry. 2015 Apr; 86(4):361.
    View in: PubMed
  32. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov; 13(11):1100-7.
    View in: PubMed
  33. Dougherty C, Silberstein SD. Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management. Pain Pract. 2015 Sep; 15(7):688-92.
    View in: PubMed
  34. Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2014 Oct; 15(14):2063-70.
    View in: PubMed
  35. Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, Sharan AD, Narouze S, Mogilner AY, Trentman TL, Ordia J, Vaisman J, Goldstein J, Mekhail N. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2015 Apr; 35(4):344-58.
    View in: PubMed
  36. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother. 2014 Sep; 15(13):1863-74.
    View in: PubMed
  37. Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014 Jul; 54(7):1258-66.
    View in: PubMed
  38. Silberstein SD. Is the migraine brain super-active? Pain. 2014 Jun; 155(6):1049-50.
    View in: PubMed
  39. Marmura MJ, Silberstein SD. Headaches caused by nasal and paranasal sinus disease. Neurol Clin. 2014 May; 32(2):507-23.
    View in: PubMed
  40. Bhambri R, Martin VT, Abdulsattar Y, Silberstein S, Almas M, Chatterjee A, Ramos E. Comparing the efficacy of eletriptan for migraine in women during menstrual and non-menstrual time periods: a pooled analysis of randomized controlled trials. Headache. 2014 Feb; 54(2):343-54.
    View in: PubMed
  41. Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question. Headache. 2013 Nov; 53(10):1651-9.
    View in: PubMed
  42. Silberstein S, McDonald SA, Goldstein J, Aurora S, Lener SE, White J, Runken MC, Saiers J, Derosier F, Lipton RB. Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: A randomized study. Cephalalgia. 2014 Apr; 34(4):268-79.
    View in: PubMed
  43. Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med. 2013 Sep; 125(5):130-8.
    View in: PubMed
  44. Silberstein SD, Edvinsson L. Is CGRP a marker for chronic migraine? Neurology. 2013 Oct 1; 81(14):1184-5.
    View in: PubMed
  45. Silberstein SD, Dodick DW. Migraine Genetics: Part II. Headache. 2013 Sep; 53(8):1218-29.
    View in: PubMed
  46. Silberstein S, Dodick D. Migraine genetics - a review: part I. Headache. 2013 Sep; 53(8):1207-17.
    View in: PubMed
  47. Silberstein SD, Marcus DA. Sumatriptan : treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013 Aug; 14(12):1659-67.
    View in: PubMed
  48. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, Degryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013 Aug 15; 331(1-2):48-56.
    View in: PubMed
  49. Silberstein S. Gastrointestinal manifestations of migraine: meeting the treatment challenges. Headache. 2013 Jun; 53 Suppl 1:1-3.
    View in: PubMed
  50. Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013 May; 27(5):385-94.
    View in: PubMed
  51. Hutchinson S, Marmura MJ, Calhoun A, Lucas S, Silberstein S, Peterlin BL. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache. 2013 Apr; 53(4):614-27.
    View in: PubMed
  52. Silberstein SD, Vodovskaia N. Trigeminal autonomic cephalalgias other than cluster headache. Med Clin North Am. 2013 Mar; 97(2):321-8.
    View in: PubMed
  53. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C. Author response. Neurology. 2013 Feb 26; 80(9):868-9.
    View in: PubMed
  54. Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, Ailani J, Schim J, Friedman DI, Charleston L, Young WB, Robertson CE, Dodick DW, Silberstein SD, Robbins MS. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches - a narrative review. Headache. 2013 Mar; 53(3):437-46.
    View in: PubMed
  55. Goadsby PJ, Silberstein SD. Migraine triggers: Harnessing the messages of clinical practice. Neurology. 2013 Jan 29; 80(5):424-5.
    View in: PubMed
  56. Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013 Jan; 33(2):101-11.
    View in: PubMed
  57. Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013 Aug; 260(8):1960-9.
    View in: PubMed
  58. Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, Charles A. Migraine headache is present in the aura phase: a prospective study. Neurology. 2012 Nov 13; 79(20):2044-9.
    View in: PubMed
  59. Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisma J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012 Dec; 32(16):1165-79.
    View in: PubMed
  60. Oshinsky ML, Sanghvi MM, Maxwell CR, Gonzalez D, Spangenberg RJ, Cooper M, Silberstein SD. Spontaneous trigeminal allodynia in rats: a model of primary headache. Headache. 2012 Oct; 52(9):1336-49.
    View in: PubMed
  61. Silberstein S. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012 Sep; 13(13):1961-8.
    View in: PubMed
  62. Pracilio VP, Silberstein S, Couto J, Bumbaugh J, Hopkins M, Ng-Mak D, Sennett C, Goldfarb NI. Measuring migraine-related quality of care across 10 health plans. Am J Manag Care. 2012 Aug; 18(8):e291-9.
    View in: PubMed
  63. Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache. 2012 Apr; 52(4):612-24.
    View in: PubMed
  64. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine--classification, characteristics and treatment. Nat Rev Neurol. 2011; 8(3):162-71.
    View in: PubMed
  65. Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, Silberstein SD. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012 Jan; 52(1):37-47.
    View in: PubMed
  66. Derosier F, Sheftell F, Silberstein S, Cady R, Ruoff G, Krishen A, Peykamian M. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache. 2012 Apr; 52(4):530-43.
    View in: PubMed
  67. Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55.
    View in: PubMed
  68. Schievink WI, Dodick DW, Mokri B, Silberstein S, Bousser MG, Goadsby PJ. Diagnostic criteria for headache due to spontaneous intracranial hypotension: a perspective. Headache. 2011 Oct; 51(9):1442-4.
    View in: PubMed
  69. Silberstein SD, Robbins MS. Targeting sleep disruption using sodium oxybate in chronic cluster headache prophylaxis. Neurology. 2011 Jul 5; 77(1):16-7.
    View in: PubMed
  70. Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: a response. Headache. 2011 Jun; 51(6):1005-8.
    View in: PubMed
  71. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011 Apr; 51(4):507-17.
    View in: PubMed
  72. Marmura MJ, Silberstein SD. Current understanding and treatment of headache disorders: five new things. Neurology. 2011 Feb 15; 76(7 Suppl 2):S31-6.
    View in: PubMed
  73. Latsko M, Silberstein S, Rosen N. Frovatriptan as preemptive treatment for fasting-induced migraine. Headache. 2011 Mar; 51(3):369-74.
    View in: PubMed
  74. Maxwell CR, Spangenberg RJ, Hoek JB, Silberstein SD, Oshinsky ML. Acetate causes alcohol hangover headache in rats. PLoS One. 2010; 5(12):e15963.
    View in: PubMed
  75. Karp BI, Sinaii N, Nieman LK, Silberstein SD, Stratton P. Migraine in women with chronic pelvic pain with and without endometriosis. Fertil Steril. 2011 Mar 1; 95(3):895-9.
    View in: PubMed
  76. Silberstein S. A new frontier for headache. Front Neurol. 2010; 1:135.
    View in: PubMed
  77. Silberstein SD. Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia. 2010 Nov; 30(11):1283.
    View in: PubMed
  78. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010 Oct; 50(9):1406-18.
    View in: PubMed
  79. Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010 Oct; 50(9):1499-506.
    View in: PubMed
  80. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011 Feb; 31(3):271-85.
    View in: PubMed
  81. Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010 Dec; 30(12):1443-57.
    View in: PubMed
  82. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011 Jan; 31(1):18-30.
    View in: PubMed
  83. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun; 50(6):921-36.
    View in: PubMed
  84. Silberstein SD. Association between restless legs syndrome and migraine. J Neurol Neurosurg Psychiatry. 2010 May; 81(5):473-5.
    View in: PubMed
  85. Silberstein SD. Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics. 2010 Apr; 7(2):153-8.
    View in: PubMed
  86. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010 Apr; 9(4):373-80.
    View in: PubMed
  87. Schwedt TJ, Silberstein SD. 14th International Headache Congress: clinical highlights. Headache. 2010 Mar; 50(3):509-19.
    View in: PubMed
  88. Silberstein SD. Migraine preventive treatment. Handb Clin Neurol. 2010; 97:337-54.
    View in: PubMed
  89. Cady RK, Goldstein J, Silberstein S, Juhász M, Ramsey K, Rodgers A, Hustad CM, Ho T. Expanding access to triptans: assessment of clinical outcome. Headache. 2009 Nov-Dec; 49(10):1402-13.
    View in: PubMed
  90. MacGregor EA, Brandes JL, Silberstein S, Jeka S, Czapinski P, Shaw B, Pawsey S. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache. 2009 Oct; 49(9):1298-314.
    View in: PubMed
  91. Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache. 2009 Oct; 49(9):1283-97.
    View in: PubMed
  92. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009 Sep; 49(8):1153-62.
    View in: PubMed
  93. Silberstein SD, Marmura MJ, Shaw J, Yu S. Headache prophylaxis with BoNTA: patient characteristics. Headache. 2010 Jan; 50(1):63-70.
    View in: PubMed
  94. Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009 May; 27(2):429-43.
    View in: PubMed
  95. Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache. 2009 Sep; 49(8):1206-13.
    View in: PubMed
  96. Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009 Feb; 49 Suppl 1:S21-33.
    View in: PubMed
  97. Rosen N, Marmura M, Abbas M, Silberstein S. Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache. 2009 Feb; 49(2):286-91.
    View in: PubMed
  98. Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon. 2009 Oct; 54(5):624-7.
    View in: PubMed
  99. Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol. 2009 Jan; 11(1):18-23.
    View in: PubMed
  100. Silberstein SD, Hutchinson SL. Diagnosis and treatment of the menstrual migraine patient. Headache. 2008 Nov-Dec; 48 Suppl 3:S115-23.
    View in: PubMed
  101. Hutchinson SL, Silberstein SD. Menstrual migraine: case studies of women with estrogen-related headaches. Headache. 2008 Nov-Dec; 48 Suppl 3:S131-41.
    View in: PubMed
  102. Silberstein SD. Recent developments in migraine. Lancet. 2008 Oct 18; 372(9647):1369-71.
    View in: PubMed
  103. Leas BF, Gagne JJ, Goldfarb NI, Rupnow MF, Silberstein S. Assessing quality of care for migraineurs: a model health plan measurement set. Popul Health Manag. 2008 Aug; 11(4):203-8.
    View in: PubMed
  104. Silberstein SD. Treatment recommendations for migraine. Nat Clin Pract Neurol. 2008 Sep; 4(9):482-9.
    View in: PubMed
  105. Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, Freitag F, Schwalen S, Ascher S, Morein J, Greenberg S, Biondi D, Hulihan J. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache. 2008 Jul; 48(7):1087-95.
    View in: PubMed
  106. Goadsby PJ, Goldberg J, Silberstein SD. Migraine in pregnancy. BMJ. 2008 Jun 28; 336(7659):1502-4.
    View in: PubMed
  107. Schere D, Silberstein SD. Intravenous lidocaine infusion for the treatment of post-acoustic neuroma resection headache: a case report. Headache. 2009 Feb; 49(2):302-3.
    View in: PubMed
  108. Mendelson J, Muppidi S, Silberstein S. Multiple intracerebral hemorrhages after cervical epidural injections. Neurology. 2008 Jun 10; 70(24 Pt 2):2415-6.
    View in: PubMed
  109. Matchar DB, Harpole L, Samsa GP, Jurgelski A, Lipton RB, Silberstein SD, Young W, Kori S, Blumenfeld A. The headache management trial: a randomized study of coordinated care. Headache. 2008 Oct; 48(9):1294-310.
    View in: PubMed
  110. Nahas SJ, Silberstein SD. Triptans: actions and reactions. Headache. 2008 Apr; 48(4):611-3.
    View in: PubMed
  111. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 Feb; 63(2):148-58.
    View in: PubMed
  112. Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Arch Neurol. 2008 Jan; 65(1):146-9.
    View in: PubMed
  113. Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008; 22(10):877-86.
    View in: PubMed
  114. Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, Mathew NT, Hulihan J, Crivera C, Rupnow MF, Mao L, Finlayson G, Greenberg SJ. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007 Nov-Dec; 47(10):1398-408.
    View in: PubMed
  115. Silberstein SD, Goldberg J. Menstrually related migraine: breaking the cycle in your clinical practice. J Reprod Med. 2007 Oct; 52(10):888-95.
    View in: PubMed
  116. Gupta MX, Silberstein SD, Young WB, Hopkins M, Lopez BL, Samsa GP. Less is not more: underutilization of headache medications in a university hospital emergency department. Headache. 2007 Sep; 47(8):1125-33.
    View in: PubMed
  117. Ashkenazi A, Silberstein S. Menstrual migraine: a review of hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2007 Aug; 8(11):1605-13.
    View in: PubMed
  118. Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache. 2007 Jun; 47(6):878-85.
    View in: PubMed
  119. Gagne JJ, Leas B, Lofland JH, Goldfarb N, Freitag F, Silberstein S. Quality of care measures for migraine: a comprehensive review. Dis Manag. 2007 Jun; 10(3):138-46.
    View in: PubMed
  120. Silberstein SD, Cady RK, Sheftell FD, Almas M, Parsons B, Albert KS. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. Headache. 2007 May; 47(5):673-82.
    View in: PubMed
  121. Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache. 2007 Apr; 47(4):500-10.
    View in: PubMed
  122. Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, Gebeline-Myers C. Patients' preference for migraine preventive therapy. Headache. 2007 Apr; 47(4):540-5.
    View in: PubMed
  123. Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB. Pharmacological approaches to managing migraine and associated comorbidities--clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr; 47(4):585-99.
    View in: PubMed
  124. Silberstein SD. Diagnostic testing in episodic migraine: should it include magnetic resonance venography? Nat Clin Pract Neurol. 2007 May; 3(5):254-5.
    View in: PubMed
  125. Lofland JH, Gagne JJ, Pizzi LT, Rupnow M, Silberstein SD. Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. J Occup Environ Med. 2007 Mar; 49(3):252-7.
    View in: PubMed
  126. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007 Mar; 47(3):355-63.
    View in: PubMed
  127. Goldberg J, Wolf A, Silberstein S, Gebeline-Myers C, Hopkins M, Einhorn K, Tolosa JE. Evaluation of an electronic diary as a diagnostic tool to study headache and premenstrual symptoms in migraineurs. Headache. 2007 Mar; 47(3):384-96.
    View in: PubMed
  128. Peres MF, Mercante JP, Guendler VZ, Corchs F, Bernik MA, Zukerman E, Silberstein SD. Cephalalgiaphobia: a possible specific phobia of illness. J Headache Pain. 2007 Feb; 8(1):56-9.
    View in: PubMed
  129. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb; 47(2):170-80.
    View in: PubMed
  130. Reinecke RD, Silberstein SD. Migrainous visual auras: a life history. Headache. 2007 Jan; 47(1):123-7.
    View in: PubMed
  131. Ashkenazi A, Abbas MA, Sharma DK, Silberstein SD. Hemicrania continua-like headache associated with internal carotid artery dissection may respond to indomethacin. Headache. 2007 Jan; 47(1):127-30.
    View in: PubMed
  132. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 Nov; 46 Suppl 4:S171-81.
    View in: PubMed
  133. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006 Nov; 46 Suppl 4:S182-91.
    View in: PubMed
  134. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006 Nov; 46 Suppl 4:S212-20.
    View in: PubMed
  135. Silberstein SD. How effective is intensive migraine education provided by migraineurs? Nat Clin Pract Neurol. 2006 Oct; 2(10):526-7.
    View in: PubMed
  136. Sun C, Lay C, Broner S, Silberstein S, Tepper S, Newman L. Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache. 2006 Oct; 46(9):1450-3.
    View in: PubMed
  137. Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci. 2006 Aug; 27(8):410-5.
    View in: PubMed
  138. Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006 Jul; 28(7):1002-11.
    View in: PubMed
  139. Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006 Jun; 22(6):1021-9.
    View in: PubMed
  140. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006 May; 46(5):773-80.
    View in: PubMed
  141. Silberstein SD, Ruoff G. Combination therapy in acute migraine treatment: the rationale behind the current treatment options. Postgrad Med. 2006 Apr; Spec No:20-6.
    View in: PubMed
  142. Goldstein J, Silberstein SD, Saper JR, Ryan RE, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache. 2006 Mar; 46(3):444-53.
    View in: PubMed
  143. Ashkenazi A, Silberstein SD. Hormone-related headache: pathophysiology and treatment. CNS Drugs. 2006; 20(2):125-41.
    View in: PubMed
  144. Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006; 20(12):1019-26.
    View in: PubMed
  145. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 2005 Nov 8; 65(9):1419-22.
    View in: PubMed
  146. Silberstein SD, Freitag FG, Rozen TD, Kudrow DB, Hewitt DJ, Jordan DM, Fisher AC, Rosenthal NR. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005 Nov-Dec; 45(10):1317-27.
    View in: PubMed
  147. Kantor D, Silberstein SD. Cervical epidural blood patch for low CSF pressure headaches. Neurology. 2005 Oct 11; 65(7):1138.
    View in: PubMed
  148. Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Headache. 2005 Oct; 45(9):1250-4.
    View in: PubMed
  149. Silberstein SD. Headaches in pregnancy. J Headache Pain. 2005 Sep; 6(4):172-4.
    View in: PubMed
  150. Martelletti P, Haimanot RT, Láinez MJ, Rapoport AM, Ravishankar K, Sakai F, Silberstein SD, Vincent M, Steiner TJ. The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). J Headache Pain. 2005 Sep; 6(4):261-3.
    View in: PubMed
  151. Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, Battikha JP, Hoffman H, Baggish J. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005 Sep; 45(8):973-82.
    View in: PubMed
  152. Harpole LH, Samsa GP, Matchar DB, Silberstein SD, Blumenfeld A, Jurgelski AE. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache. 2005 Sep; 45(8):1048-55.
    View in: PubMed
  153. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005 Sep; 80(9):1126-37.
    View in: PubMed
  154. Silberstein SD. Cardiovascular risk factors associated with migraine. Lancet Neurol. 2005 Jul; 4(7):391-2.
    View in: PubMed
  155. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol. 2005 Jun; 18(3):289-92.
    View in: PubMed
  156. Gupta M, Silberstein SD. Therapeutic options in the management of headache attributed to rhinosinusitis. Expert Opin Pharmacother. 2005 May; 6(5):715-22.
    View in: PubMed
  157. Rosenberg JH, Silberstein SD. The headache of SAH responds to sumatriptan. Headache. 2005 May; 45(5):597-8.
    View in: PubMed
  158. Silberstein SD. Chronic daily headache. J Am Osteopath Assoc. 2005 Apr; 105(4 Suppl 2):23S-29S.
    View in: PubMed
  159. Silberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr; 45 Suppl 1:S57-65.
    View in: PubMed
  160. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005 Apr; 45(4):315-24.
    View in: PubMed
  161. Siow HC, Young WB, Silberstein SD. Neuroleptics in headache. Headache. 2005 Apr; 45(4):358-71.
    View in: PubMed
  162. Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther. 2005 Feb; 27(2):154-65.
    View in: PubMed
  163. O'Connor W, Silberstein SD. MRI of a brain under pressure. Headache. 2005 Jan; 45(1):68-9.
    View in: PubMed
  164. Silberstein SD. Headaches in pregnancy. Neurol Clin. 2004 Nov; 22(4):727-56.
    View in: PubMed
  165. Silberstein SD. Migraine. Discov Med. 2004 Oct; 4(23):270-6.
    View in: PubMed
  166. Ashkenazi A, Silberstein SD. Headache management for the pain specialist. Reg Anesth Pain Med. 2004 Sep-Oct; 29(5):462-75.
    View in: PubMed
  167. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004 Jul 27; 63(2):261-9.
    View in: PubMed
  168. Rozen TD, Shanske S, Otaegui D, Lu J, Young WB, Bradley K, DiMauro S, Silberstein SD. Study of mitochondrial DNA mutations in patients with migraine with prolonged aura. Headache. 2004 Jul-Aug; 44(7):674-7.
    View in: PubMed
  169. Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr Pain Headache Rep. 2004 Jun; 8(3):244-50.
    View in: PubMed
  170. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004 May; 44(5):414-25.
    View in: PubMed
  171. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache. 2004 May; 44 Suppl 1:S20-30.
    View in: PubMed
  172. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004 Apr; 61(4):490-5.
    View in: PubMed
  173. Freitag FG, Lake A, Lipton R, Cady R, Diamond S, Silberstein S. Inpatient treatment of headache: an evidence-based assessment. Headache. 2004 Apr; 44(4):342-60.
    View in: PubMed
  174. Blumenfeld AM, Dodick DW, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004 Apr; 22(2):167-75.
    View in: PubMed
  175. Silberstein S. Botulinum neurotoxins: origins and basic mechanisms of action. Pain Pract. 2004 Mar; 4 Suppl 1:S19-26.
    View in: PubMed
  176. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004 Feb; 44(2):120-30.
    View in: PubMed
  177. Silberstein SD. Headaches due to nasal and paranasal sinus disease. Neurol Clin. 2004 Feb; 22(1):1-19, v.
    View in: PubMed
  178. Silberstein SD. Migraine. Lancet. 2004 Jan 31; 363(9406):381-91.
    View in: PubMed
  179. Dodick D, Blumenfeld A, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Clin Dermatol. 2004 Jan-Feb; 22(1):76-81.
    View in: PubMed
  180. Gerth WC, Sarma S, Hu XH, Silberstein SD. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med. 2004 Jan; 46(1):48-54.
    View in: PubMed
  181. Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med. 2004; 55:505-18.
    View in: PubMed
  182. Silberstein SD. Chronic migraine: diagnosis and management strategy. Rev Neurol Dis. 2004; 1(3):155-60.
    View in: PubMed
  183. Evans RW, Lipton RB, Silberstein SD. The prevalence of migraine in neurologists. Neurology. 2003 Nov 11; 61(9):1271-2.
    View in: PubMed
  184. Silberstein SD. Topiramate in migraine prevention. Expert Rev Neurother. 2003 Nov; 3(6):761-71.
    View in: PubMed
  185. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache. 2003 Sep; 43(8):884-91.
    View in: PubMed
  186. Silberstein SD, Aoki KR. Botulinum toxin type A: myths, facts, and current research. Headache. 2003 Jul-Aug; 43 Suppl 1:S1.
    View in: PubMed
  187. Silberstein SD. Neurotoxins in the neurobiology of pain. Headache. 2003 Jul-Aug; 43 Suppl 1:S2-8.
    View in: PubMed
  188. Ashkenazi A, Silberstein SD. The evolving management of migraine. Curr Opin Neurol. 2003 Jun; 16(3):341-5.
    View in: PubMed
  189. Silberstein SD, McKinstry RC. The death of idiopathic intracranial hypertension? Neurology. 2003 May 13; 60(9):1406-7.
    View in: PubMed
  190. Silberstein SD. Analyses of cost-effectiveness of migraine therapies should consider multiple measures. J Manag Care Pharm. 2003 May-Jun; 9(3):279-80; author reply 280-1.
    View in: PubMed
  191. Bigal ME, Lipton RB, Silberstein SD. Re: chronic daily headache in children and adolescents presenting to tertiary headache clinics. Headache. 2003 Apr; 43(4):419-21.
    View in: PubMed
  192. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003 Mar; 43(3):171-8.
    View in: PubMed
  193. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb; 43(2):144-66.
    View in: PubMed
  194. Chatterton ML, Lofland JH, Shechter A, Curtice WS, Hu XH, Lenow J, Smullens SN, Nash DB, Silberstein SD. Reliability and validity of the migraine therapy assessment questionnaire. Headache. 2002 Nov-Dec; 42(10):1006-15.
    View in: PubMed
  195. Silberstein SD, Welch KM. Painkiller headache. Neurology. 2002 Oct 8; 59(7):972-4.
    View in: PubMed
  196. Silberstein SD, Massiou H, McCarroll KA, Lines CR. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache. 2002 Oct; 42(9):917-23.
    View in: PubMed
  197. Mendes PM, Silberstein SD, Young WB, Rozen TD, Paolone MF. Intravenous propofol in the treatment of refractory headache. Headache. 2002 Jul-Aug; 42(7):638-41.
    View in: PubMed
  198. Silberstein SD, Liu D. Drug overuse and rebound headache. Curr Pain Headache Rep. 2002 Jun; 6(3):240-7.
    View in: PubMed
  199. Silberstein SD, Peres MF. Hemicrania continua. Arch Neurol. 2002 Jun; 59(6):1029-30.
    View in: PubMed
  200. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002 Jun; 42(6):515-8.
    View in: PubMed
  201. Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache. 2002 Jun; 42(6):530-1.
    View in: PubMed
  202. Evans RW, Silberstein SD. Diagnostic testing for chronic daily headache. Headache. 2002 Jun; 42(6):556-9.
    View in: PubMed
  203. Silberstein SD. Pharmacological profile and clinical characteristics of frovatriptan in the acute treatment of migraine: introduction. Headache. 2002 Apr; 42 Suppl 2:S45-6.
    View in: PubMed
  204. Silberstein SD. Tricyclic antidepressant medication, stress management therapy, and their combination in the management of chronic tension-type headache. Curr Neurol Neurosci Rep. 2002 Mar; 2(2):105-7.
    View in: PubMed
  205. Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function: a population-based, case-control study. Neurology. 2002 Feb 12; 58(3):422-7.
    View in: PubMed
  206. Siow HC, Young WB, Peres MF, Rozen TD, Silberstein SD. Hemiplegic cluster. Headache. 2002 Feb; 42(2):136-9.
    View in: PubMed
  207. Dodick DW, Silberstein S, Dahlöf CG. Is there a preferred triptan? Headache. 2002 Jan; 42(1):1-7.
    View in: PubMed
  208. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. Headache. 2002 Jan; 42(1):85.
    View in: PubMed
  209. Silberstein SD. Clinical results of botulinum toxin type a treatment of migraine headache. Aesthet Surg J. 2002 Jan; 22(1):91-3.
    View in: PubMed
Silberstein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department